Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives.

Ye F, Bauer JA, Pietenpol JA, Shyr Y.

BMC Genomics. 2012;13 Suppl 8:S3. doi: 10.1186/1471-2164-13-S8-S3. Epub 2012 Dec 17.

2.

RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.

Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA.

Breast Cancer Res. 2010;12(3):R41. doi: 10.1186/bcr2595. Epub 2010 Jun 24.

3.

Median absolute deviation to improve hit selection for genome-scale RNAi screens.

Chung N, Zhang XD, Kreamer A, Locco L, Kuan PF, Bartz S, Linsley PS, Ferrer M, Strulovici B.

J Biomol Screen. 2008 Feb;13(2):149-58. doi: 10.1177/1087057107312035. Epub 2008 Jan 23.

PMID:
18216396
4.

GUItars: a GUI tool for analysis of high-throughput RNA interference screening data.

Goktug AN, Ong SS, Chen T.

PLoS One. 2012;7(11):e49386. doi: 10.1371/journal.pone.0049386. Epub 2012 Nov 20.

5.

Robust statistical methods for hit selection in RNA interference high-throughput screening experiments.

Zhang XD, Yang XC, Chung N, Gates A, Stec E, Kunapuli P, Holder DJ, Ferrer M, Espeseth AS.

Pharmacogenomics. 2006 Apr;7(3):299-309.

PMID:
16610941
6.

Using iterative cluster merging with improved gap statistics to perform online phenotype discovery in the context of high-throughput RNAi screens.

Yin Z, Zhou X, Bakal C, Li F, Sun Y, Perrimon N, Wong ST.

BMC Bioinformatics. 2008 Jun 5;9:264. doi: 10.1186/1471-2105-9-264.

7.

Deciphering Seed Sequence Based Off-Target Effects in a Large-Scale RNAi Reporter Screen for E-Cadherin Expression.

Adams R, Nicke B, Pohlenz HD, Sohler F.

PLoS One. 2015 Sep 11;10(9):e0137640. doi: 10.1371/journal.pone.0137640. eCollection 2015.

8.

An effective method for controlling false discovery and false nondiscovery rates in genome-scale RNAi screens.

Zhang XD.

J Biomol Screen. 2010 Oct;15(9):1116-22. doi: 10.1177/1087057110381783. Epub 2010 Sep 20.

PMID:
20855561
9.

The use of SSMD-based false discovery and false nondiscovery rates in genome-scale RNAi screens.

Zhang XD, Lacson R, Yang R, Marine SD, McCampbell A, Toolan DM, Hare TR, Kajdas J, Berger JP, Holder DJ, Heyse JF, Ferrer M.

J Biomol Screen. 2010 Oct;15(9):1123-31. doi: 10.1177/1087057110381919. Epub 2010 Sep 17.

PMID:
20852024
10.

A Multivariate Computational Method to Analyze High-Content RNAi Screening Data.

Rameseder J, Krismer K, Dayma Y, Ehrenberger T, Hwang MK, Airoldi EM, Floyd SR, Yaffe MB.

J Biomol Screen. 2015 Sep;20(8):985-97. doi: 10.1177/1087057115583037. Epub 2015 Apr 27.

12.

TOPS: a versatile software tool for statistical analysis and visualization of combinatorial gene-gene and gene-drug interaction screens.

Muellner MK, Duernberger G, Ganglberger F, Kerzendorfer C, Uras IZ, Schoenegger A, Bagienski K, Colinge J, Nijman SM.

BMC Bioinformatics. 2014 Apr 8;15:98. doi: 10.1186/1471-2105-15-98.

13.

High-throughput RNAi screening of human kinases identifies predictors of clinical outcome in colorectal cancer patients treated with oxaliplatin.

Lin M, Zhang Y, Li A, Tang E, Peng J, Tang W, Zhang Y, Lu L, Xiao Y, Wei Q, Yin L, Li H.

Oncotarget. 2015 Jun 30;6(18):16774-85.

14.

Statistical methods for analysis of high-throughput RNA interference screens.

Birmingham A, Selfors LM, Forster T, Wrobel D, Kennedy CJ, Shanks E, Santoyo-Lopez J, Dunican DJ, Long A, Kelleher D, Smith Q, Beijersbergen RL, Ghazal P, Shamu CE.

Nat Methods. 2009 Aug;6(8):569-75. doi: 10.1038/nmeth.1351. Review.

15.

Error rates and powers in genome-scale RNAi screens.

Zhang XD, Marine SD, Ferrer M.

J Biomol Screen. 2009 Mar;14(3):230-8. doi: 10.1177/1087057109331475. Epub 2009 Feb 11.

PMID:
19211781
16.

High-throughput RNAi screening for the identification of novel targets.

Henderson MC, Azorsa DO.

Methods Mol Biol. 2013;986:89-95. doi: 10.1007/978-1-62703-311-4_6.

PMID:
23436407
17.

RNAi screening: new approaches, understandings, and organisms.

Mohr SE, Perrimon N.

Wiley Interdiscip Rev RNA. 2012 Mar-Apr;3(2):145-58. doi: 10.1002/wrna.110. Epub 2011 Sep 22. Review.

18.

Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.

Spänkuch B, Kurunci-Csacsko E, Kaufmann M, Strebhardt K.

Oncogene. 2007 Aug 23;26(39):5793-807. Epub 2007 Mar 19.

PMID:
17369857
19.

Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.

Garimella SV, Gehlhaus K, Dine JL, Pitt JJ, Grandin M, Chakka S, Nau MM, Caplen NJ, Lipkowitz S.

Breast Cancer Res. 2014 Apr 17;16(2):R41. doi: 10.1186/bcr3645.

20.

SbacHTS: spatial background noise correction for high-throughput RNAi screening.

Zhong R, Kim MS, White MA, Xie Y, Xiao G.

Bioinformatics. 2013 Sep 1;29(17):2218-20. doi: 10.1093/bioinformatics/btt358. Epub 2013 Jun 28.

Supplemental Content

Support Center